In the study, a long-term health economic analysis was determined using the IQVIA CORE Diabetes Model – which allows the calculation of long-term outcomes, based on the best data currently available – to establish the cost-effectiveness for funding Dexcom rtCGM technology versus testing with finger pricks. The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits.
https://www.gurufocus.com/news/1990755/dexcom-rtcgm-is-likely-to-be-costsaving-study-suggests